Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model
Li Qin, Peter B. Gilbert, Dean Follmann, Dongfeng Li

TL;DR
This paper develops methods to evaluate immune responses as surrogate endpoints in vaccine trials using case-cohort sampling and Cox models, addressing missing data and unmeasured responses.
Contribution
It introduces novel estimands and trial designs for surrogate endpoint assessment under the principal stratification framework with missing immune response data.
Findings
Proposed estimands measure immune response as a surrogate in Cox models.
Two innovative trial designs predict missing immune responses for surrogate validation.
Simulation studies demonstrate the effectiveness of the proposed methods.
Abstract
Assessing immune responses to study vaccines as surrogates of protection plays a central role in vaccine clinical trials. Motivated by three ongoing or pending HIV vaccine efficacy trials, we consider such surrogate endpoint assessment in a randomized placebo-controlled trial with case-cohort sampling of immune responses and a time to event endpoint. Based on the principal surrogate definition under the principal stratification framework proposed by Frangakis and Rubin [Biometrics 58 (2002) 21--29] and adapted by Gilbert and Hudgens (2006), we introduce estimands that measure the value of an immune response as a surrogate of protection in the context of the Cox proportional hazards model. The estimands are not identified because the immune response to vaccine is not measured in placebo recipients. We formulate the problem as a Cox model with missing covariates, and employ novel trial…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
